Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-SLAMF7 CAR T cells||Autologous Anti-SLAMF7 CAR T-cells|SLAMF7 CAR-T cells||Anti-SLAMF7 CAR T cells are T-cells that express a chimeric antigen receptor derived from the SLAMF7 (CS1)-targeting antibody elotuzumab, which potentially results in anti-tumor activity against SLAMF7-expressing tumor cells (PMID: 29089311).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03958656||Phase I||Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid||T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma||Completed||USA||0|